Pathophysiology of Ischemic Heart Disease: Complete 2026 Doctor’s Guide

By Dr. Sagar Rajkuwar, ENT Specialist, Nashik, Maharashtra, India
🌐 www.entspecialistinnashik.com

Short answer: The pathophysiology of ischemic heart disease starts with endothelial dysfunction inside the coronary arteries, triggered by LDL cholesterol, hypertension, diabetes mellitus, smoking and oxidative stress. Oxidised LDL is engulfed by macrophages, forming foam cells and fatty streaks; smooth-muscle proliferation and extracellular matrix deposition build a fibrous plaque. Plaques may stay stable (producing stable angina) or rupture, exposing tissue factor, activating platelets and triggering a thrombus — the root of unstable angina, NSTEMI, and STEMI. Reduced flow produces myocardial ischaemia through a mismatch between oxygen supply and demand; prolonged ischaemia causes necrosis, arrhythmia, remodelling, and ischaemic cardiomyopathy. If you are reading about pathophysiology of ischemic heart disease, this 2026 guide — built on WHO, CDC, NHS, AHA/ACC 2023, and ESC 2024 — walks through every step.

Table of Contents

1. Introduction
2. Normal Coronary Anatomy & Physiology
3. Oxygen Supply vs Demand
4. Endothelial Dysfunction — The First Step
5. Lipid Retention & Oxidation
6. Foam-Cell Formation & Fatty Streak
7. Fibrous Plaque Development
8. Plaque Vulnerability & Rupture
9. Thrombosis & Acute Coronary Syndrome
10. Ischaemic Cascade in the Myocardium
11. Reperfusion Injury
12. Chronic Changes: Remodelling & Cardiomyopathy
13. Microvascular Ischaemia & Vasospasm
14. Modifying Risk Factors in the Pathway
15. External Video Resource
16. FAQs
17. Conclusion
18. References

1. Introduction

Ischemic heart disease (IHD), also called coronary artery disease (CAD), is the leading global killer. Understanding the pathophysiology of ischemic heart disease is central to prevention, diagnosis and treatment — every drug and procedure in modern cardiology targets a specific step of this cascade.

2. Normal Coronary Anatomy & Physiology

• The left main coronary artery divides into LAD and LCx
• The right coronary artery (RCA) supplies inferior wall and RV
• Perfusion occurs during diastole
• Oxygen extraction is already ~75% at rest — any demand increase must be met by flow
• Coronary flow reserve is regulated by endothelium-derived nitric oxide and metabolic autoregulation

3. Oxygen Supply vs Demand

• Supply: coronary flow × arterial oxygen content
• Demand: heart rate × wall tension × contractility
• Any mismatch produces ischaemia
• Typical triggers: exertion, cold, emotion, large meals, anaemia, hypoxia

Related reading: See IHD causes and prevention and the 4 stages of ischaemic heart disease.

4. Endothelial Dysfunction — The First Step

• Caused by shear stress, LDL, nicotine, hyperglycaemia, oxidative stress
• Loss of nitric-oxide-mediated vasodilation
• Increased permeability, adhesion molecules (VCAM-1, ICAM-1)
• Pro-thrombotic surface develops

This earliest change in the pathophysiology of ischemic heart disease is detectable years before symptoms.

5. Lipid Retention & Oxidation

• LDL particles penetrate the intima
• Oxidised by reactive oxygen species
• Trigger inflammation via scavenger receptors
• Elevated Lipoprotein(a) accelerates the process

6. Foam-Cell Formation & Fatty Streak

• Monocytes enter the intima, become macrophages
• Macrophages engulf oxidised LDL via scavenger receptors (CD36, SR-A)
• Lipid-laden foam cells accumulate
• Visible as a fatty streak — present in children by age 10

7. Fibrous Plaque Development

• Vascular smooth-muscle cells migrate from media to intima
• Produce extracellular matrix (collagen, elastin, proteoglycans)
• Fibrous cap over a lipid-rich necrotic core forms
• Calcification occurs with age
• Stable plaques narrow the lumen gradually → produce stable angina on exertion

8. Plaque Vulnerability & Rupture

8.1 Features of a vulnerable plaque

• Thin fibrous cap (<65 µm)
• Large necrotic lipid core (>40% of plaque volume)
• Many macrophages, few smooth-muscle cells
• Positive remodelling (plaque grows outward)
• Neovascularisation and intraplaque haemorrhage
• Spotty calcification

8.2 Triggers of rupture

• Sympathetic surges (early morning, Monday mornings)
• Severe emotional stress
• Intense physical exertion
• Cold exposure
• Cocaine, amphetamines
• Air pollution spikes
• Acute infections (influenza, COVID-19)

9. Thrombosis & Acute Coronary Syndrome

• Rupture exposes tissue factor and collagen
• Platelets adhere via GP Ib and GP IIb/IIIa receptors
• Coagulation cascade activated → thrombin, fibrin
• Partial occlusion → unstable angina / NSTEMI
• Complete occlusion → STEMI
• Dissolution/embolisation → MINOCA

This acute step of the pathophysiology of ischemic heart disease is why aspirin, P2Y12 inhibitors and heparin are life-saving.

10. Ischaemic Cascade in the Myocardium

1. Metabolic alterations (within seconds)
2. Diastolic dysfunction (within 10–30 seconds)
3. Systolic dysfunction (within a minute)
4. ECG changes (ST-depression, T-wave inversion, then ST-elevation)
5. Chest pain / anginal equivalents
6. Irreversible necrosis after ~20–30 minutes of total occlusion

11. Reperfusion Injury

• Restoration of flow after prolonged ischaemia can paradoxically worsen damage
• Mechanisms: calcium overload, oxidative stress, mitochondrial permeability transition pore opening, microvascular obstruction
• No-reflow phenomenon after PCI
• Research directions: cyclosporine A, remote ischaemic conditioning, hypothermia

Deeper reading: Can ischemia be reversed? explains how much of this cascade can still be undone.

12. Chronic Changes: Remodelling & Cardiomyopathy

• After MI, viable myocardium hypertrophies, infarcted segments scar
• Chamber dilates — eccentric remodelling
• Reduced ejection fraction → HFrEF
• Neurohormonal activation (RAAS, sympathetic) worsens remodelling
• Modern “four pillars” (ACE-I/ARB/ARNI, beta-blocker, MRA, SGLT2 inhibitor) reverse remodelling

13. Microvascular Ischaemia & Vasospasm

• Small-vessel (<500 µm) dysfunction causes INOCA/ANOCA
• Impaired coronary flow reserve & raised IMR
• Variant angina — focal spasm (e.g., proximal LAD) — treated with CCBs and nitrates
• Common in women; often missed on angiography

14. Modifying Risk Factors in the Pathway

• Statins reduce LDL, stabilise plaque, improve endothelium
• Antihypertensives lower wall stress
• SGLT2 inhibitors reduce events via metabolic & anti-fibrotic pathways
• Antiplatelets prevent thrombus propagation
• Low-dose colchicine targets residual inflammation
• Lifestyle: Mediterranean/DASH diet, exercise, smoking cessation, stress management

15. External Video Resource

Watch a visual animation of the pathophysiology of ischemic heart disease:

YouTube: Pathophysiology of IHD – Osmosis / Armando Hasudungan

16. FAQs

Q1. What is the first step in IHD pathophysiology?

Endothelial dysfunction — detectable years before symptoms.

Q2. Does cholesterol alone cause IHD?

No — it is one driver among many. Hypertension, diabetes, smoking, inflammation, and genetics all contribute.

Q3. Why do plaques rupture?

Thin fibrous caps, inflammation, lipid-rich cores and sympathetic surges all contribute.

Q4. What is the ischaemic cascade?

Stepwise sequence from metabolic changes → diastolic → systolic dysfunction → ECG → pain → necrosis.

Q5. Can the process be reversed?

Partially — aggressive risk-factor control, statins and lifestyle regress early plaque.

Q6. What is MINOCA?

MI with non-obstructive coronary arteries — plaque disruption, vasospasm, SCAD, Takotsubo mechanisms.

Q7. How does diabetes accelerate the pathway?

Hyperglycaemia impairs endothelium, raises oxidative stress, and promotes a diffuse multivessel pattern.

Q8. Is inflammation treatable?

Yes — low-dose colchicine 0.5 mg daily reduces residual inflammatory risk in stable CAD.

17. Conclusion

The pathophysiology of ischemic heart disease is a decades-long cascade starting with endothelial injury, progressing through atherosclerotic plaque development, and ending in rupture, thrombosis, infarction and remodelling. Each step is a target for therapy — from lifestyle and statins at the earliest stages to antiplatelets, revascularisation and heart-failure pillars at the end. The earlier you intervene, the more of the cascade you can halt.

18. References

1. Libby P. The vascular biology of atherosclerosis. Braunwald’s Heart Disease, 12th ed. 2022.
2. Vrints C, et al. 2024 ESC Guidelines on Chronic Coronary Syndromes.
3. Byrne RA, et al. 2023 ESC Guidelines on ACS.
4. Thygesen K, et al. Fourth Universal Definition of MI. Circulation 2018; 2023 update.
5. Nidorf SM, et al. LoDoCo2 trial. NEJM 2020.
6. WHO Cardiovascular Diseases Fact Sheet 2024.

📞 ENT Consultation & Surgery

Dr. Sagar Rajkuwar (MS-ENT)
Prabha ENT Clinic, Ambad, Nashik
📱 7387590194 | 9892596635
🌐 www.entspecialistinnashik.com

Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Audiogram results should be interpreted by a qualified audiologist or ENT specialist. If you have sudden hearing loss, severe dizziness, ear discharge, or other concerning symptoms, seek medical evaluation promptly. Always consult a qualified cardiologist for IHD care.